No Data
No Data
Shandong Pharmaceutical (600529.SH): List of goods subject to new tariffs imposed by the US in May, not involving the types of products exported by the company to the US
Gelonghui, May 28 | Shandong Pharmaceutical (600529.SH) said on the investor interactive platform that the list of goods subject to new tariffs imposed by the US in May 2024 did not cover the types of products the company exported to the US.
Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shandong Pharmaceutical GlassLtd fair value estimate is CN¥24.29 With CN¥28.73 share price, Shandong Pharmaceutical GlassLtd appears to be tr
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a sad week for Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529), who've watched their investment drop 11% to CN¥28.48 in the week since the company reported its quarterly result. The
Shandong Pharmaceutical (600529.SH): Net profit of 221 million yuan in the first quarter increased 32.59% year-on-year
Gelonghui, April 22丨Shandong Pharmaceutical (600529.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,267 million yuan, up 2.50% year on year; net profit attributable to shareholders of listed companies was 221 million yuan, up 32.59% year on year; after deducting non-net profit of 210 million yuan, up 36.14% year on year; basic earnings per share were 0.33 yuan.
Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) Investors Are Less Pessimistic Than Expected
It's not a stretch to say that Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) price-to-earnings (or "P/E") ratio of 28.6x right now seems quite "middle-of-the-road" compared to the market in Ch
Is Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Shandong Pharmaceutical GlassLtd (SHSE:600529) has had a great run on the share market with its stock up by a significant 14% over the last three months. As most would know, fundamentals are what us
No Data